Specialty Section for the Treatment of Gastric Cancer
| Gastric cancer may be
the most seriously mismanaged malignancy from a surgical perspective in the USA |
||
| Paul H. Sugarbaker, M.D. | April 1999 | |
Sugarbaker Oncology Associates
maintains an active program in treatment of gastric cancer. We
offer the most experienced, multidisciplinary group of
oncologists in the Washington D.C. area. Our treatment strategies
include cytoreductive surgery, intraoperative intraperitoneal
chemotherapy and hyperthermia. Our associates have numerous publications describing our innovative treatment
strategies.
Gastric cancer is the second most
frequently diagnosed cancer in the world. The United States is
fortunate in that the incidence of this dreadful disease is lower
than many other countries. Nevertheless, the Survelience,
Epidemiology, and End Results (SEER) Program of the National
Cancer Institute reports that over 19,000 people in the United
States were diagnosed with gastric cancer and over 1,100 died of
the disease in 1994.*
| * | Surveillance, Epidemiology, and End Results (SEER) Program public use CD-ROM (1973-1994), National Cancer Institute, DCPC, Surveillance Program, Cancer Statistics Branch, released May 1997, based on the August 1996 Submission. |
| The surgeon must take
responsibility not only for mass in the stomach, but also for the microscopic residual disease; i.e. what surgery may leave behind. |
||
| Paul H. Sugarbaker, M.D. | April 1999 | |
| Home | Intro to SOA | Quick Tour |
| WHC Tour | Specialty Treatment Programs | FARGO |
| Patient Resources | Professional Resources | Your Hospitalization |